By Jaime Llinares Taboada
Cizzle Biotechnology Holdings PLC said Thursday that it has entered into a marketing agreement with consulting firm Behnke Group to enhance its expansion in the U.S.
The U.K.-based diagnostics developer said that Behnke will help it find new partnerships with healthcare providers and businesses in the U.S.
“The USA is a strategically important market for us because of the high prevalence of lung cancer and the resulting loss of life, which could be improved through the implementation of a simple blood test,” Executive Chairman Allan Syms said.
Shares at 0758 GMT were up 2.9% at 1.80 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
Source link
